Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer

NCT03009981 is registered in ClinicalTrials.gov with Alliance Foundation Trials, LLC. as lead sponsor.

NCT NCT03009981
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03009981 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
Lead sponsor
Alliance Foundation Trials, LLC.
Phase
Phase 3
Overall status
Completed
Start date
March 6, 2017
Completion date
June 25, 2025
Enrollment
504 (actual)
Sites
69

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer